Andrew Bottomley
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Andrew Bottomley has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
Fabio Efficace
4 shared publications- Henning Flechtner
Clinic for Psychiatry and Psychotherapy of Children and Adolescents, University of Cologne, Cologne, Germany
2 shared publications Martine Piccart
2 shared publicationsPatrick Therasse
2 shared publicationsRonald Thomas
From the Quality of Life Unit, European Organization for Research and Treatment of Cancer Data Center, Brussels, Belgium; Clinical Consultant, Palmerston North, New Zealand; Academic Palliative Medicine Unit, and University of Sheffield, Royal Hallamshire Hospital, Sheffield, United Kingdom
2 shared publicationsTanja Cufer
2 shared publications
Latest Publications
- Open Access
- 1 January 2006
- Published by Springer Nature in Health and Quality of Life Outcomes
- Vol. 4 (1) , 1-9
An integrated psychological strategy for advanced colorectal cancer patients
There is evidence regarding the usefulness of psychosocial intervention to improve health related quality of life (HRQOL) in adult cancer patients. The aim of this report is to describe an integrated approach and to evaluate its feasibility in routine clinical practice in 98 advanced colorectal cancer (ACC) patients during chronomodulated chemotherapy.
- 1 January 2006
- Published by Springer Nature in Health and Quality of Life Outcomes
- Vol. 4 (1) , 1-9
Open AccessAn integrated psychological strategy for advanced colorectal cancer patients
There is evidence regarding the usefulness of psychosocial intervention to improve health related quality of life (HRQOL) in adult cancer patients. The aim of this report is to describe an integrated approach and to evaluate its feasibility in routine clinical practice in 98 advanced colorectal cancer (ACC) patients during chronomodulated chemotherapy.
- 1 May 2005
- Published by Elsevier in The Lancet Oncology
- Vol. 6 (5) , 287-294
Health-related quality of life in survivors of locally advanced breast cancer: an international randomised controlled phase III trial
- 1 May 2005
- Published by Elsevier in The Lancet Oncology
- Vol. 6 (5) , 287-294
Health-related quality of life in survivors of locally advanced breast cancer: an international randomised controlled phase III trial
- 1 July 2004
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 22 (13) , 2576-2586
Randomized, Controlled Trial Investigating Short-Term Health-Related Quality of Life With Doxorubicin and Paclitaxel Versus Doxorubicin and Cyclophosphamide As First-Line Chemotherapy in Patients With Metastatic Breast Cancer: European Organization for Research and Treatment of Cancer Breast Cancer Group, Investigational Drug Branch for Breast Cancer and the New Drug Development Group Study
Purpose: To compare health-related quality of life (HRQOL) in patients with metastatic breast cancer receiving the combination of doxorubicin and paclitaxel (AT) or doxorubicin and cyclophosphamide (AC) as first-line chemotherapy treatment. Patients and Methods: Eligible patients (n = 275) with anthracycline-naive measurable metastatic breast cancer were randomly assigned to AT (doxorubicin 60 mg/m2 as an intravenous bolus plus paclitaxel 175 mg/m2 as a 3-hour infusion) or AC (doxorubicin 60 mg/m2 plus cyclophosphamide 600 mg/m2) every 3 weeks for a maximum of six cycles. Dose escalation of paclitaxel (200 mg/m2) and cyclophosphamide (750 mg/m2) was planned at cycle 2 to reach equivalent myelosuppression in the two groups. HRQOL was assessed with the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire C30 and the EORTC Breast Module at baseline and the start of cycles 2, 4, and 6, and 3 months after the last cycle. Results: Seventy-nine percent of the patients (n = 219) completed a baseline measure. However, there were no statistically significant differences in HRQOL between the two treatment groups. In both groups, selected aspects of HRQOL were impaired over time, with increased fatigue, although some clinically significant improvements in emotional functioning were seen, as well as a reduction in pain over time. Overall, global quality of life was maintained in both treatment groups. Conclusion: This information is important when advising women patients of the expected HRQOL consequences of treatment regimens and should help clinicians and their patients make informed treatment decisions.
- 1 July 2004
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 22 (13) , 2576-2586
Randomized, Controlled Trial Investigating Short-Term Health-Related Quality of Life With Doxorubicin and Paclitaxel Versus Doxorubicin and Cyclophosphamide As First-Line Chemotherapy in Patients With Metastatic Breast Cancer: European Organization for Research and Treatment of Cancer Breast Cancer Group, Investigational Drug Branch for Breast Cancer and the New Drug Development Group Study
Purpose: To compare health-related quality of life (HRQOL) in patients with metastatic breast cancer receiving the combination of doxorubicin and paclitaxel (AT) or doxorubicin and cyclophosphamide (AC) as first-line chemotherapy treatment. Patients and Methods: Eligible patients (n = 275) with anthracycline-naive measurable metastatic breast cancer were randomly assigned to AT (doxorubicin 60 mg/m2 as an intravenous bolus plus paclitaxel 175 mg/m2 as a 3-hour infusion) or AC (doxorubicin 60 mg/m2 plus cyclophosphamide 600 mg/m2) every 3 weeks for a maximum of six cycles. Dose escalation of paclitaxel (200 mg/m2) and cyclophosphamide (750 mg/m2) was planned at cycle 2 to reach equivalent myelosuppression in the two groups. HRQOL was assessed with the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire C30 and the EORTC Breast Module at baseline and the start of cycles 2, 4, and 6, and 3 months after the last cycle. Results: Seventy-nine percent of the patients (n = 219) completed a baseline measure. However, there were no statistically significant differences in HRQOL between the two treatment groups. In both groups, selected aspects of HRQOL were impaired over time, with increased fatigue, although some clinically significant improvements in emotional functioning were seen, as well as a reduction in pain over time. Overall, global quality of life was maintained in both treatment groups. Conclusion: This information is important when advising women patients of the expected HRQOL consequences of treatment regimens and should help clinicians and their patients make informed treatment decisions.
- 1 August 2003
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 21 (15) , 2982-2992
Health-Related Quality of Life in Non–Small-Cell Lung Cancer: Methodologic Issues in Randomized Controlled Trials
Purpose: Non–small-cell lung cancer (NSCLC), a leading cause of cancer-related deaths in both developed and developing countries, heavily impacts patient health-related quality of life (HRQOL). Although recent research has found many positive and significant steps in randomized controlled trials (RCTs) in which HRQOL has been used as an outcome, questions remain regarding methodologic quality and impact value of HRQOL outcome assessments in some RCTs. To date, no detailed systematic review exists of HRQOL methodology in NSCLC RCTs.
- 1 August 2003
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 21 (15) , 2982-2992
Health-Related Quality of Life in Non–Small-Cell Lung Cancer: Methodologic Issues in Randomized Controlled Trials
Purpose: Non–small-cell lung cancer (NSCLC), a leading cause of cancer-related deaths in both developed and developing countries, heavily impacts patient health-related quality of life (HRQOL). Although recent research has found many positive and significant steps in randomized controlled trials (RCTs) in which HRQOL has been used as an outcome, questions remain regarding methodologic quality and impact value of HRQOL outcome assessments in some RCTs. To date, no detailed systematic review exists of HRQOL methodology in NSCLC RCTs.
- 1 February 2003
- Published by Elsevier in European Journal of Cancer
- Vol. 39 (3) , 275-285
The challenges and achievements involved in implementing Quality of Life research in cancer clinical trials
- 1 February 2003
- Published by Elsevier in European Journal of Cancer
- Vol. 39 (3) , 275-285
The challenges and achievements involved in implementing Quality of Life research in cancer clinical trials
- 1 October 2002
- Published by Elsevier in The Lancet Oncology
- Vol. 3 (10) , 620-628
Quality of life in patients undergoing systemic therapy for advanced breast cancer
- 1 October 2002
- Published by Elsevier in The Lancet Oncology
- Vol. 3 (10) , 620-628
Quality of life in patients undergoing systemic therapy for advanced breast cancer
- 1 August 2002
- Published by Elsevier in European Journal of Cancer
- Vol. 38 (12) , 1611-1614
The development and utilisation of the European Organisation for research and treatment of cancer quality of life group item bank
- 1 August 2002
- Published by Elsevier in European Journal of Cancer
- Vol. 38 (12) , 1611-1614
The development and utilisation of the European Organisation for research and treatment of cancer quality of life group item bank
- 1 May 2002
- Published by Elsevier in The Lancet
- Vol. 359 (9317) , 1537-1538
Metastatic colorectal cancer: treatment challenges and quality of life
- 1 May 2002
- Published by Elsevier in The Lancet
- Vol. 359 (9317) , 1537-1538
Metastatic colorectal cancer: treatment challenges and quality of life
- Open Access
- 1 April 2002
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 7 (2) , 120-125
The Cancer Patient and Quality of Life
Over the last decade, clinicians have accepted that while survival and disease-free survival are critical factors for cancer patients, overall quality-of-life is fundamental. This review considers recent developments in the field of quality of life, oncological challenges and future directions.
- 1 April 2002
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 7 (2) , 120-125
Open AccessThe Cancer Patient and Quality of Life
Over the last decade, clinicians have accepted that while survival and disease-free survival are critical factors for cancer patients, overall quality-of-life is fundamental. This review considers recent developments in the field of quality of life, oncological challenges and future directions.